Wedbush Cuts Disc Medicine (NASDAQ:IRON) Price Target to $88.00

Disc Medicine (NASDAQ:IRON) had its price objective lowered by Wedbush from $110.00 to $88.00 in a research note issued to investors on Tuesday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock.

IRON has been the topic of a number of other reports. Wells Fargo & Company lifted their target price on Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. BMO Capital Markets reduced their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Tuesday. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Finally, Truist Financial boosted their price target on shares of Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a report on Monday, November 10th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and an average price target of $104.82.

Disc Medicine Trading Down 1.8%

Disc Medicine stock opened at $63.35 on Tuesday. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -11.84 and a beta of 0.88. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $99.50. The firm’s 50 day moving average price is $77.24 and its two-hundred day moving average price is $75.12. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45.

Insider Transactions at Disc Medicine

In other Disc Medicine news, CFO Jean M. Franchi sold 7,081 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total value of $463,593.07. Following the completion of the sale, the chief financial officer owned 71,343 shares in the company, valued at $4,670,826.21. This represents a 9.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00. Following the sale, the insider directly owned 37,793 shares of the company’s stock, valued at $2,973,931.17. This trade represents a 14.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 284,761 shares of company stock worth $24,913,484. 3.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after buying an additional 2,807 shares during the last quarter. Millennium Management LLC increased its holdings in Disc Medicine by 1,277.1% in the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after buying an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after acquiring an additional 3,454 shares in the last quarter. KLP Kapitalforvaltning AS raised its position in Disc Medicine by 24.3% during the second quarter. KLP Kapitalforvaltning AS now owns 4,600 shares of the company’s stock valued at $244,000 after acquiring an additional 900 shares in the last quarter. Finally, CWM LLC lifted its stake in Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after acquiring an additional 711 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Management said it will pursue a traditional U.S. approval pathway for lead drug bitopertin after the FDA declined a fast‑track route, giving investors a clearer regulatory path rather than abandoning the program. Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod
• Positive Sentiment: Several sell‑side firms (Cantor Fitzgerald, Stifel) have maintained constructive ratings (buy/overweight) even as some trimmed targets, which can support institutional interest and limit downside. Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)
• Neutral Sentiment: Market commentary and valuation checks are active as investors parse the FDA Complete Response Letter and implications for timing — some outlets ran valuation pieces and transcripts of the company investor call. Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program
• Neutral Sentiment: Reported short‑interest prints are noisy/insignificant in the latest data, so today’s move looks driven largely by event‑driven trading and position rebalancing rather than a classic short‑squeeze dynamic.
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and adding headline pressure that can deter buyers. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
• Negative Sentiment: Multiple insiders sold sizable blocks this week (CEO, CFO, COO and others), which investors often interpret as negative signal about near‑term outlook even though insiders still hold meaningful equity. John Quisel Sells 13,264 Shares of Disc Medicine (NASDAQ:IRON) Stock
• Negative Sentiment: HC Wainwright and other firms cut near‑ and long‑term EPS forecasts and several shops trimmed price targets, lowering the near‑term valuation baseline until regulatory clarity and data timelines are resolved.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.